Status:
COMPLETED
An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Osteoporosis
Eligibility:
FEMALE
Brief Summary
This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practic...
Detailed Description
Preventing bone loss is an important concern for women during post-menopausal period. Menopause significantly speeds bone loss and increases the risk for osteoporosis. This study was to investigate th...
Eligibility Criteria
Inclusion
- Postmenopausal women who need to prevent/treat osteoporosis
- Subject who got raloxifene/cholecalciferol combination therapy prescription with confirmation by the investigator's medical decision
- Subjects who can consent voluntarily
Exclusion
- Patients for whom use of raloxifene/cholecalciferol combination therapy is prohibited
- Pregnant women, nursing women or child-bearing aged females deemed capable of pregnancy
Key Trial Info
Start Date :
November 6 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 13 2020
Estimated Enrollment :
3907 Patients enrolled
Trial Details
Trial ID
NCT04788290
Start Date
November 6 2017
End Date
July 13 2020
Last Update
March 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Pharmaceutical Company Limited
Seoul, South Korea, 05545